Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Todd Johnson

MOHS-Micrographic Surgery Chicago, IL Medical Doctor

NPI 1033208418 CMS profile 535045

1765 N Elston Ave, Suite 110, Chicago, IL 60642

Open in the dashboard

General payments

$10,363

483 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Todd Johnson of Chicago, IL is reported in the CMS Open Payments database as having received $10,363 across 483 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $997 43
2024 General $2,095 100
2023 General $1,899 91
2022 General $1,098 58
2021 General $997 54
2020 General $1,062 54
2019 General $2,214 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todd Johnson
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Todd Johnson were reported at $997. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Todd Johnson MOHS-Micrographic Surgery median Middle half National median
2019 $2,214 $316 $106–$785 $163
2020 $1,062 $162 $68–$412 $114
2021 $997 $243 $87–$654 $132
2022 $1,098 $300 $102–$887 $149
2023 $1,899 $364 $125–$1,010 $160
2024 $2,095 $445 $142–$1,108 $164
2025 $997 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,981 98 payments
  2. Regeneron Healthcare Solutions, Inc. $1,103 41 payments
  3. Genzyme Corporation $973 43 payments
  4. Sun Pharmaceutical Industries Inc. $727 42 payments
  5. Lilly USA, LLC $718 32 payments
  6. PruGen, Inc. Pharmaceuticals $651 9 payments
  7. LEO Pharma Inc. $632 38 payments
  8. Amgen Inc. $365 14 payments
  9. Pfizer Inc. $363 22 payments
  10. Novartis Pharmaceuticals Corporation $344 17 payments
  11. Other $2,507 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,128 480 payments
  2. Education $236 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,228 51 payments
  2. DUPIXENT Inflammation And Immunology $799 32 payments
  3. SKYRIZI $723 36 payments
  4. RINVOQ $712 39 payments
  5. TALTZ $704 31 payments
  6. HUMIRA $556 33 payments
  7. ILUMYA $452 26 payments
  8. ADBRY $429 30 payments
  9. Otezla $344 13 payments
  10. OLUMIANT $299 11 payments
  11. Other $5,739 310 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

530

Median for Dermatology: 534

Drug cost

$123,439

Median for Dermatology: $67,151

Branded share of claims

8.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 25 $114,139
Clobetasol Propionate Generic 28 $1,433
Fluocinonide Generic 23 $1,314
Betamethasone Dipropionate Generic 30 $1,154
Gentamicin Sulfate Generic 26 $766
Triamcinolone Acetonide Generic 51 $740
Doxycycline Hyclate Generic 57 $720
Cephalexin Generic 47 $601
Ketoconazole Generic 40 $594
Metronidazole Generic 13 $512

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$422,667

Medicare's payments for the services billed

Medicare patients

557

Average age 75

Services billed

5,259

275 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 43%
Ischemic heart disease 21%
Osteoporosis 19%
Diabetes 18%
Cancer 16%
Chronic kidney disease 15%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $331
  • Regeneron Healthcare Solutions, Inc. $279
$610 — —
RINVOQ
  • AbbVie, Inc. $235
$235 — —
SKYRIZI
  • AbbVie, Inc. $224
$224 — —
ADBRY
  • LEO Pharma Inc. $176
$176 — —
OPZELURA
  • Incyte Corporation $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

483 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record